Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Transferência de genes para pacientes com doença falciforme

28 de outubro de 2026 atualizado por: Children's Hospital Medical Center, Cincinnati

Transferência de genes para pacientes com doença falciforme usando um vetor de lentivírus de gama globina: um estudo piloto de fase 1/2 de rótulo aberto

The purpose of this Phase 1/2 study is to determine the feasibility and safety of stem cell collection and gamma-globin gene transfer, and success of gene correction in subjects with sickle cell disease

Visão geral do estudo

Status

Rescindido

Condições

Intervenção / Tratamento

Descrição detalhada

This study will assess the feasibility, safety and efficacy of gene transfer using ARU-1801 (CD34+ cells transduced with the gamma-globin lentiviral vector). Gene transfer will occur ex-vivo into CD34+ enriched human bone marrow or plerixafor-mobilized peripheral blood hematopoietic stem cells (HSC) collected from subjects with severe sickle cell disease (SCD). Subjects will undergo reduced intensity chemotherapy conditioning with single-dose melphalan to facilitate engraftment of ex-vivo ARU-1801 via IV infusion. Subjects will return to the study site at regular intervals for follow-up for 2 years after the ARU-1801 infusion. It is anticipated that a separate long-term follow-up (LTFU) clinical study will be initiated, in which all subjects completing the 2 year study visit will be asked to consent and enroll, and will followed for a further 13 years.

Tipo de estudo

Intervencional

Inscrição (Real)

7

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Cincinnati Children's Hospital Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 45 anos (Adulto)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria

  • Signed informed consent form.

  • Has confirmed diagnosis of sickle cell disease (SCD)

  • Has severe sickle cell disease, defined as one or more of the following:

    1. Minimum of two episodes of clinically diagnosed acute chest syndrome (ACS) requiring hospital admission, or one life threatening episode of ACS requiring intensive care unit (ICU) admission for exchange transfusion and/or intubation, or frequent ACS episodes which necessitate treatment with chronic transfusion therapy.
    2. Frequent painful vaso-occlusive episodes (VOEs) which significantly interfere with normal life activities, defined as a history of 2 or more severe acute sickle pain events per year requiring additional treatment at a medical facility outside of home pain management over the preceding 2-year period prior to study enrollment, or that necessitate chronic transfusion therapy.
    3. Subjects on chronic transfusion therapy for severe disease symptoms other than those listed above, and which interfere with normal life activities.
  • Has failed hydroxyurea therapy, was unable to tolerate hydroxyurea therapy, or has actively made the choice to not take the recommended daily hydroxyurea advised for severe disease (Note: must be off hydroxyurea therapy for 2 months prior to stem cell collection). If refusing hydroxyurea, the subject must document that they have been educated about the benefits and continue to refuse the treatment. Patients placed on chronic transfusion therapy instead of hydroxyurea for severe disease are eligible. Subjects unable to take hydroxyurea due to financial or safety monitoring constraints are eligible.

  • Has adequate functional status and organ function as determined at Screening.

Exclusion Criteria

  • Female subjects who are pregnant or lactating/breastfeeding.
  • Female subjects who are not surgically sterile, postmenopausal or who refuse to practice effective method of birth control as determined by the Investigator for one year after receiving the study drug. Women must also agree not to breastfeed for 1 year after receiving the study drug.
  • Any participant of reproductive potential who refuses to agree to use an appropriate contraceptive method determined by the Investigator, for 1 year after receiving the study drug.
  • Patients with an active malignant disease or receiving treatment for any type of cancer (except squamous cell carcinoma, basal cell carcinoma, or carcinoma in situ of the skin).
  • Current diagnosis or history of hepatitis B, hepatitis C, or HIV.
  • Has received another study drug within 30 days, or 5 half-lives of the last dose (whichever is longer), prior to screening.
  • Has severe obstruction, restriction or diffusion defect on pulmonary function tests.
  • Has uncontrolled bacterial, viral or fungal infections within 1 month prior to starting the conditioning part of the study. Subjects with fever should wait for symptoms to resolve before starting the conditioning part of the study.
  • Has a history of stroke or is at moderate to high risk of primary stroke (eg receiving chronic transfusions or hydroxyurea for primary prevention of stroke; has severe cerebral vasculopathy defined as moderate stenosis in >2 arterial segments; and/or has sever stenosis/occlusion in ≤2 segments in the polygon of Willis or presence of Moyamoya-like disease).
  • Patients with alpha thalassemia sickle cell disease.
  • Has previous liver biopsy showing cirrhosis, bridging hepatic fibrosis, or active hepatitis; or has received chronic transfusions and has previous evidence of iron overload and evidence of liver fibrosis by noninvasive liver imaging.
  • Has a matched sibling donor, unless the subject has declined this option or this option is not feasible. Documentation must be included as part of the informed consent process for subjects who decline this option.
  • Has a known hypersensitivity to any study treatments (e.g. melphalan, plerixafor).

Other protocol-defined inclusion-exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Cuidados de suporte
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: ARU-1801

Autologous CD34+ hematopoietic stem cells transduced ex-vivo with gamma-globin lentiviral vector. Administered via IV infusion.

Autologous CD34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector

  • Subjects with sickle cell anemia will undergo hematopoietic stem cell procurement by bone marrow harvest or apheresis after mobilization with plerixafor
  • Reduced intensity chemotherapy conditioning with single dose melphalan will be used to facilitate engraftment of ex-vivo transduced cells.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Number of Participants With Grade 3 Allergic Reaction
Prazo: From infusion (Day 0) to 30 days post-infusion

Number of Participants with Grade 3 allergic reaction associated with infusion of transduced cell product

From infusion (Day 0) to 30 days post-infusion
Number of Participants Grade 4 Infection
Prazo: From infusion (Day 0) to 30 days post-infusion

Number of Grade 4 infection following infusion of transduced cell product uncontrolled for ≥14 days

From infusion (Day 0) to 30 days post-infusion
Total Number of Grade 4 Neutropenia
Prazo: From date of chemotherapy clearance visit to to 30 days post-infusion

Number of participants with Grade 4 neutropenia lasting >1 month following melphalan

From date of chemotherapy clearance visit to to 30 days post-infusion
Number of Participants With Grade 3 or 4 Toxicity Events
Prazo: From infusion (Day 0) to 30 days post-infusion

Number of Participants with Grade 3 or 4 organ toxicity attributable to study procedures

From infusion (Day 0) to 30 days post-infusion
Total Number of Adverse Events (AEs) and Serious Adverse Events (SAE)
Prazo: From infusion (Day 0) to 30 days post-infusion
From infusion (Day 0) to 30 days post-infusion
Number of Death Due to Study Procedures
Prazo: From screening to the end of study, and up to 12 months.
From screening to the end of study, and up to 12 months.
Number of Hematological Malignancy
Prazo: From infusion (Day 0) to end of study, up to 12 months

Number of hematological malignancy due to vector insertion

From infusion (Day 0) to end of study, up to 12 months
Number of Hematological Cancer
Prazo: From infusion (Day 0) to end of study, up to 12 months.

Number of hematological cancer related to investigational product or study medications/procedures

From infusion (Day 0) to end of study, up to 12 months.
Time to Neutrophil Recovery
Prazo: From infusion (Day 0) to end of study, up to 12 months.

Duration of neutropenia following conditioning (defined as the time from first measurement where absolute neutrophil count (ANC) < 500 cells/µL to first of 3 consecutive absolute neutrophil count measurements on 3 consecutive days with ANC ≥500 cells/µL)

From infusion (Day 0) to end of study, up to 12 months.
Time to Platelet Recovery
Prazo: From infusion (Day 0) to end of study, up to 12 months.

Duration of thrombocytopenia following conditioning (defined as the time from first measurement where platelet count < 50,000 cells/µL to the first of 3 consecutive platelet counts on 3 consecutive days > 50,000 cells/µL and independent of platelet transfusion for ≥7 days consecutive days)

From infusion (Day 0) to end of study, up to 12 months.
≥8x10⁶kg Viable CD34+ Cells
Prazo: Date of Enrollment to Infusion (day 0).

Number of subjects with a total number of CD34+ cells recovered from all collections combined (mobilized peripheral blood and bone marrow) of at least ≥8x10⁶kg viable CD34+ cells

Date of Enrollment to Infusion (day 0).
≥4x10⁶ CD34+ Cells/kg Body Weight Transduced
Prazo: Date of Enrollment to Infusion (day 0).

Proportion of subjects for which a minimum of 4x10⁵ CD34+ cells/kg body weight from all collections combined have been successfully transduced

Date of Enrollment to Infusion (day 0).
Number of Subjects With Bone Marrow Aspirates With ≥1% Gene-marked Cells
Prazo: Infusion (Day 0) to 1 year post infusion.

Number of subjects with bone marrow aspirates at 1-year post-infusion with ≥1% gene-marked cells

Infusion (Day 0) to 1 year post infusion.

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of HBF^G16D
Prazo: Infusion to 12 months post-infusion

Percentage of HBF^G16D relative to total Hemoglobin

Infusion to 12 months post-infusion
Change in Proportion of Antisickling/Sickling Hemoglobin
Prazo: Enrollment to Month 24

Evaluation of the longitudinal change in the ratio of total antisickling hemoglobin fractions, comprising Fetal Hemoglobin (HbF), the gene-modified hemoglobin variant (HbFG16D), and Hemoglobin A2 (HbA2), relative to Sickling Hemoglobin (HbS). This outcome assesses the stable expression of the therapeutic transgene and the successful shift in the underlying hemoglobin profile post-infusion. Measurements will be performed using Capillary Zone Electrophoresis (CZE) to quantify the individual percentages of each hemoglobin fraction. The antisickling proportion is defined as the sum percentage: (HbF+HbFG16D+HbA2). This value will be compared between the baseline (pre-conditioning/pre-infusion) and the evaluable period through month 24 post-infusion to determine the sustained pancellular distribution of non-sickling hemoglobins. Higher values are considered a successful outcome.

Enrollment to Month 24
Percentage of F-retics (Fetal Hemoglobin Content in Reticulocytes)
Prazo: Infusion to 12 months post-infusion

This measure quantifies the proportion of newly formed red blood cells (reticulocytes) containing detectable levels of fetal hemoglobin (HbF). Because reticulocytes reflect the most recent erythropoietic activity (the last 24-48 hours), this percentage serves as a real-time indicator of the induction of HbF at the erythroid precursor level. This is measured by flow cyctometry.

Infusion to 12 months post-infusion
Percent VCN at 6 Months
Prazo: Infusion to 6 months post-infusion

This measure assesses the percentage of infusion product Vector copy number (VCN) at six months post-infusion in each patient. VCN analysis is performed on DNA from the white blood cell fraction using quantitative polymerase chain reaction (qPCR).

Infusion to 6 months post-infusion

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Stella M. Davies, MB BS, PhD, MRCP, Children's Hospital Medical Center, Cincinnati

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

1 de julho de 2014

Conclusão Primária (Real)

31 de outubro de 2022

Conclusão do estudo (Real)

31 de outubro de 2022

Datas de inscrição no estudo

Enviado pela primeira vez

30 de junho de 2014

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de julho de 2014

Primeira postagem (Estimado)

10 de julho de 2014

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

28 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever